drugset / Trial / NCT02216214

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214

Phase 4 Completed 888 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.

Timeline

Start
2014-10-07
Primary completion
2017-11-29
Completion
2018-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg Oral
Subject Mirabegron Other / unclassified 50 mg Oral

Indications